Syros Long Term Debt from 2010 to 2024
| SYRS Stock | USD 5.10 0.10 2.00% |
Long Term Debt | First Reported 2014-12-31 | Previous Quarter 34.6 M | Current Value 29.7 M | Quarterly Volatility 18.6 M |
Check Syros Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Syros main balance sheet or income statement drivers, such as Depreciation And Amortization of 2.4 M, Interest Expense of 5.4 M or Selling General Administrative of 18.9 M, as well as many exotic indicators such as Price To Sales Ratio of 21.1, Dividend Yield of 0.0 or PTB Ratio of 13.91. Syros financial statements analysis is a perfect complement when working with Syros Pharmaceuticals Valuation or Volatility modules.
Syros | Long Term Debt |
Latest Syros Pharmaceuticals' Long Term Debt Growth Pattern
Below is the plot of the Long Term Debt of Syros Pharmaceuticals over the last few years. Long-term debt is a debt that Syros Pharmaceuticals has held for over one year. Long-term debt appears on Syros Pharmaceuticals balance sheet and also includes long-term leases. The most common forms of long term debt are bonds payable, long-term notes payable, mortgage payable, pension liabilities, and lease liabilities. In the corporate world, long-term debt is generally used to fund big-ticket items, such as machinery, buildings, and land. The total of long-term debt reported on Syros Pharmaceuticals balance sheet is the sum of the balances of all categories of long-term debt. It is debt that is not due within the current year and is often considered to be financing activities that are to be repaid over several years. Syros Pharmaceuticals' Long Term Debt historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Syros Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| Long Term Debt | 10 Years Trend |
|
Long Term Debt |
| Timeline |
Syros Long Term Debt Regression Statistics
| Arithmetic Mean | 17,119,270 | |
| Geometric Mean | 1,649,303 | |
| Coefficient Of Variation | 112.81 | |
| Mean Deviation | 18,087,888 | |
| Median | 206,000 | |
| Standard Deviation | 19,311,746 | |
| Sample Variance | 372.9T | |
| Range | 40.6M | |
| R-Value | 0.79 | |
| Mean Square Error | 152.1T | |
| R-Squared | 0.62 | |
| Significance | 0.0005 | |
| Slope | 3,403,405 | |
| Total Sum of Squares | 5221.2T |
Syros Long Term Debt History
Other Fundumenentals of Syros Pharmaceuticals
Syros Pharmaceuticals Long Term Debt component correlations
About Syros Pharmaceuticals Financial Statements
There are typically three primary documents that fall into the category of financial statements. These documents include Syros Pharmaceuticals income statement, its balance sheet, and the statement of cash flows. Syros Pharmaceuticals investors use historical funamental indicators, such as Syros Pharmaceuticals's Long Term Debt, to determine how well the company is positioned to perform in the future. Although Syros Pharmaceuticals investors may use each financial statement separately, they are all related. The changes in Syros Pharmaceuticals's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Syros Pharmaceuticals's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Syros Pharmaceuticals Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Syros Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Long Term Debt | 34.6 M | 21.4 M | |
| Short and Long Term Debt | 7.7 M | 8.1 M | |
| Short and Long Term Debt Total | 62.1 M | 34.7 M | |
| Long Term Debt Total | 46.7 M | 49.1 M | |
| Long Term Debt To Capitalization | 0.67 | 0.71 |
Pair Trading with Syros Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Syros Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Syros Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving together with Syros Stock
| 0.68 | EQ | Equillium | PairCorr |
Moving against Syros Stock
| 0.54 | VALN | Valneva SE ADR | PairCorr |
| 0.5 | DOMH | Dominari Holdings | PairCorr |
| 0.46 | VBIV | VBI Vaccines | PairCorr |
| 0.44 | VCEL | Vericel Corp Ord | PairCorr |
The ability to find closely correlated positions to Syros Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Syros Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Syros Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Syros Pharmaceuticals to buy it.
The correlation of Syros Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Syros Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Syros Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Syros Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out the analysis of Syros Pharmaceuticals Correlation against competitors. For more information on how to buy Syros Stock please use our How to Invest in Syros Pharmaceuticals guide.You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Complementary Tools for Syros Stock analysis
When running Syros Pharmaceuticals' price analysis, check to measure Syros Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Syros Pharmaceuticals is operating at the current time. Most of Syros Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Syros Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Syros Pharmaceuticals' price. Additionally, you may evaluate how the addition of Syros Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation |
Is Syros Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Syros Pharmaceuticals. If investors know Syros will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Syros Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (5.06) | Revenue Per Share 0.224 | Quarterly Revenue Growth (0.03) | Return On Assets (0.46) | Return On Equity (2.37) |
The market value of Syros Pharmaceuticals is measured differently than its book value, which is the value of Syros that is recorded on the company's balance sheet. Investors also form their own opinion of Syros Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Syros Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Syros Pharmaceuticals' market value can be influenced by many factors that don't directly affect Syros Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Syros Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Syros Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Syros Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.